MoonLake Immunotherapeutics
US ˙ NasdaqCM ˙ KY61559X1045

SecurityMLTX / MoonLake Immunotherapeutics
InstitutionSquarepoint Ops LLC
Latest Disclosed Ownership110,217 shares
Latest Disclosed Value $ 2,054,445
Squarepoint Ops LLC ownership in MLTX / MoonLake Immunotherapeutics

On May 15, 2026 - Squarepoint Ops LLC filed a 13F-HR form disclosing ownership of 110,217 shares of MoonLake Immunotherapeutics (US:MLTX) valued at $2,054,445 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 121,640 shares of MoonLake Immunotherapeutics. This represents a change in shares of -9.39% during the quarter. The current value of the position is $2,013,665 USD.

Squarepoint Ops LLC has a history of taking positions in derivatives of the underlying security (MLTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

MLTX / MoonLake Immunotherapeutics Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 110,217 -11,423 -9.39 2,054 28.13 0.0024
2026-02-13 2025-12-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 121,640 90,950 296.35 1,603 628.64 0.0017
2025-11-14 2025-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 30,690 13,119 74.66 220 -73.46 0.0002
2025-08-27 2025-06-30 13F/A-1 MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 17,571 629 3.71 829 25.42 0.0009
2025-08-14 2025-06-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 17,571 629 829 0.0009
2025-08-27 2025-03-31 13F/A-1 MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 16,942 16,942 662 0.0008
2025-05-15 2025-03-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 16,942 16,942 662 0.0008
2025-02-14 2024-12-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 0 -6,402 -100.00 0 -100.00
2024-11-14 2024-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 6,402 -938 -12.78 323 0.00 0.0005
2024-08-14 2024-06-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 7,340 7,340 323 0.0005
2024-05-15 2024-03-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 0 -18,903 -100.00 0 -100.00
2024-02-14 2023-12-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 18,903 4,994 35.90 1,142 44.07 0.0022
2023-11-14 2023-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 13,909 -27,522 -66.43 793 -62.50 0.0020
2023-08-14 2023-06-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 41,431 41,431 2,113 0.0065
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-13 2025-12-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-11-14 2025-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 12,900 92 n/a n/a n/a
2025-08-27 2025-03-31 13F/A MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-05-15 2025-03-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 0 0 n/a n/a n/a
2025-02-14 2024-12-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 13,000 704 n/a n/a n/a
2024-11-14 2024-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 12,500 550 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-11-14 2024-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Put 12,500 550 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.